AIRNA Raises Oversubscribed $155 Million Series B Financing to Fund Phase 1/2 Clinical Trial for Alpha-1 Antitrypsin Deficiency and Future Pipeline Financing led by Venrock Healthcare Capital ...

today unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), the next program within its liver franchise. Prime Medicine expects to file an investigational new ...

today unveiled a preclinical program for the treatment of alpha-1 antitrypsin deficiency (AATD), the next program within its liver franchise. Prime Medicine expects to file an investigational new drug ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

AIR-001 is designed to restore functional alpha-1 antitrypsin (M-AAT) protein production by precisely repairing the SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver ...

Liver diseases can be inherited (such as Wilson disease and alpha 1-antitrypsin deficiency) or acquired (for example hepatitis and liver cancer). This study identifies transcription factor 7-like ...

alpha-1 antitrypsin. This means that individuals with A1PI deficiency are at high risk of the chronic lung condition emphysema as they are more likely to succumb to infections and environmental ...

The inhaled AAT product could launch in 2030, targeting a $2 billion market for alpha-1 antitrypsin deficiency. Kamada aims to lower costs ... We’re also collecting CT scan data, lung density, and ...

Drug-induced hepatitis is an example of acute liver inflammation, as it will resolve once the offending drug is stopped. The same is seen with hepatitis A, which will spontaneously clear once the ...

Air pollution, occupational exposure, or a genetic Alpha-1 antitrypsin (AATD) deficiency also are causes. Chronic coughing, mucus production, and shortness of breath are common with COPD. It tends to ...